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Abstract
Background: Friedreich ataxia is a progressive neurodegenerative disorder caused by GAA triplet repeat expansions or
point mutations in the FXN gene and, ultimately, a deficiency in the levels of functional frataxin protein. Heterozygous
carriers of the expansion express approximately 50% of normal frataxin levels yet manifest no clinical symptoms, suggesting
that therapeutic approaches that increase frataxin may be effective even if frataxin is raised only to carrier levels. Small
molecule HDAC inhibitor compounds increase frataxin mRNA and protein levels, and have beneficial effects in animal
models of FRDA.
Methodology/Principal Findings: To gather data supporting the use of frataxin as a therapeutic biomarker of drug
response we characterized the intra-individual stability of frataxin over time, determined the contribution of frataxin from
different components of blood, compared frataxin measures in different cell compartments, and demonstrated that frataxin
increases are achieved in peripheral blood mononuclear cells. Frataxin mRNA and protein levels were stable with repeated
sampling over four and 15 weeks. In the 15-week study, the average CV was 15.6% for protein and 18% for mRNA. Highest
levels of frataxin in blood were in erythrocytes. As erythrocytes are not useful for frataxin assessment in many clinical trial
situations, we confirmed that PBMCs and buccal swabs have frataxin levels equivalent to those of whole blood. In addition,
a dose-dependent increase in frataxin was observed when PBMCs isolated from patient blood were treated with HDACi.
Finally, higher frataxin levels predicted less severe neurological dysfunction and were associated with slower rates of
neurological change.
Conclusions/Significance: Our data support the use of frataxin as a biomarker of drug effect. Frataxin levels are stable over
time and as such a 1.5 to 2-fold change would be detectable over normal biological fluctuations. Additionally, our data
support buccal cells or PBMCs as sources for measuring frataxin protein in therapeutic trials.
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Introduction
Friedreich ataxia (FRDA) is an autosomal recessive neurode-
generative disorder caused by a GAA triplet repeat expansion or
point mutations in the FXN gene. With a prevalence of 1 in 50,000
FRDA is the most common inherited ataxia. Most individuals with
FRDA (97%) have an expanded GAA triplet repeat in the first
intron of the frataxin gene in both alleles [1]. The triplet repeat
leads to decreased frataxin mRNA transcription and, ultimately, a
deficiency in the level of frataxin protein. The majority of the
remaining 3% of patients have the triplet repeat expansion in one
allele and a point mutation in the other allele [2]; such point
mutations also lead to deficiency of functional frataxin.
Frataxin is a ubiquitous, nuclear-encoded mitochondrial protein
[3]. The deficiency in frataxin is associated with iron accumulation
in the mitochondria, impairment of Fe-S cluster containing
enzymes, increased sensitivity to oxidative stress, and deficits of
respiratory chain complex activities [4–6]. While frataxin is
expressed in all tissues, FRDA mostly impacts neural and cardiac
tissue for reasons that are not completely understood [7–9].
Clinical manifestations of the disease include ataxia, loss of
coordination and reflexes, cardiomyopathy, scoliosis, diabetes and
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optic atrophy [10–12]. The age of onset of disease manifestations
is variable, but typically occurs in late childhood or early
adolescence and correlates with GAA repeat length on the shorter
allele. There is no approved treatment for FRDA.
Individuals who are heterozygous ‘‘carriers’’ of the triplet GAA
expansion have levels of frataxin that are approximately 50% of
normal levels yet they manifest no clinical symptoms. This suggests
that therapeutic approaches that increase frataxin may be effective
even if frataxin is raised only to the level of a carrier. Small
molecule HDAC inhibitor (HDACi) compounds increase histone
acetylation at the frataxin locus and increase frataxin mRNA and
protein levels [13]. Increases in frataxin mRNA and protein after
HDACi treatment have been observed in vitro using primary
lymphocytes isolated from patient blood [14]. Beneficial effects of
HDACi have also been documented in animal models of FRDA
[14–16].
The interpretation of clinical trials in FRDA with agents that
change frataxin expression will require biological markers of drug
response. A variety of clinical measures including examination-
based scales and performance measure composites have been
validated in FRDA, but their sensitivity to change as reflected in
natural history data is limited. Similarly, biochemical markers of
FRDA are at present limited. Techniques to measure peripheral
frataxin levels have been developed, but many of the practical
features of their use (such as short-term and long-term variability
independent of therapy) have not yet been defined [17–20]. In
addition, data linking serial clinical change with frataxin level,
confirming frataxin levels as appropriate targets in the disease,
have not yet been obtained.
Here we characterize the correlation of frataxin protein levels
with disease severity, the stability of frataxin levels over time, and
the contribution of frataxin from different components of whole
blood. We then demonstrate that increases in frataxin mRNA and
protein can be quantified in peripheral blood mononuclear cells
(PBMCs) following HDACi treatment. Finally, we investigate
predictive ability of frataxin measurements on neurological
progression, and discuss its impact as a biomarker in measuring
response to therapies aimed at increasing frataxin.
Methods
Ethics Statement
All protocols were approved by the IRB at the University of
Pennsylvania or the Children’s Hospital of Philadelphia, or by the
Ethics Committee at Erasme Hospital, Brussels, Belgium, and
written informed consent was obtained from each subject.
Patients
Cohort 1 contained individuals enrolled in a clinical trial of an
agent unrelated to frataxin expression [21] while cohort 3 were
randomly selected subjects from the clinical populations of the
Children’s Hospital of Philadelphia. Clinical and demographic
information for patients (Cohort 3) involved in ex vivo studies (GAA
repeat length, age, etc.) were typically self-reported or derived
from the Friedreich Ataxia Clinical Outcome Measures database
(n = 98) [22]. Cohort 2 contained individuals selected based on the
ability of a patient and related carrier to provide weekly blood
donations for a 15-week duration. Clinical information was not
collected from cohort 2 subjects.
Whole Blood Collection and Fractionation
Blood was drawn into K2EDTA Vacutainer tubes (BD
Biosciences, San Jose, CA) unless specified otherwise and shipped
overnight at ambient temperature. Upon receipt, blood was either
frozen at 280uC until further processing or was immediately
processed for isolation of erythrocytes or PBMCs.
For fractionation of whole blood, freshly drawn blood was
separated into fractions that were enriched for plasma, PBMCs,
platelets, granulocytes, or erythrocytes. First, 4.5 mL of whole
blood was diluted 1:2 in phosphate buffered saline (PBS) and
slowly layered over 6 mL lymphocyte separation medium (LSM).
The blood was centrifuged for 40 minutes at 1,000 rpm at room
temperature. After separation, the top plasma layer, the ‘‘buffy
coat’’ layer containing PBMC, and the LSM layer were
transferred to new 15 mL conical tubes. The volume of the tubes
containing plasma, LSM, and the remaining erythrocyte pellet
were each increased to 9 mL with PBS. The volume of the tube
containing PBMCs was increased to 4.5 mL with PBS. To isolate
platelets, the PBMC fraction was centrifuged an additional two
times for 10 minutes at 1,000 rpm at room temperature. After the
first spin, the supernatant containing platelets was transferred into
a new 15 mL conical tube, the PBMC pellet was resuspended in
4.5 mL PBS, centrifuged, and the supernatant was transferred into
the conical tube containing platelets. The PBMC pellet was then
resuspended in 9 mL PBS.
In a parallel, but separate fractionation procedure, 4.5 mL of
whole blood was diluted 1:2 in 16PBS, centrifuged, and the
erythrocyte pellet was further separated into granulocytes using
three, sequential washes with 10 mL Erythrocyte Lysis Buffer
(Buffer EL) (Qiagen, Valencia, CA). Each wash with Buffer EL
was performed for 5 minutes at room temperature and was
followed by centrifugation at 1,000 rpm for 10 minutes at room
temperature. After the third wash, the granulocyte pellet was
resuspended in 9 mL in PBS and stored at 280uC until further
processing or was immediately processed for frataxin protein
measurements.
PBMCs were isolated from approximately 30 mL of EDTA-
anticoagulated whole blood using differential centrifugation and
Lymphocyte Separation Medium (LSM) (MP Biomedicals, Solon,
OH) or, alternatively, by transferring the blood into Cell
Preparation Tubes (BD Biosciences). After separation, PBMCs
were washed with PBS, incubated for 5–10 minutes with Buffer EL
to ensure complete removal of erythrocytes, and then washed a
final time with PBS to remove residual Buffer EL. Cell pellets were
then stored at 280uC until further processing or resuspended in
cell culture medium and treated with HDACi as described below.
Treatment of PBMCs with HDAC Inhibitors
Freshly isolated PBMCs were cultured in RPMI 1640 medium
supplemented with 15% FBS, L-glutamine, penicillin, and
streptomycin. Cells were cultured in 6-well plates in the presence
of the HDAC inhibitor RGFP109 or DMSO as a vehicle control.
RGFP109 was added to cells for a final concentration of 1, 2.5, 5,
or 10 mM, and DMSO was added for a final 0.1% concentration.
Cells were incubated for 48 or 72 hours before harvesting total
mRNA or protein. Total mRNA was isolated using an RNeasy
Mini Kit (Qiagen) following the manufacturer’s protocol and
including an optional on-column DNAse digestion.
Buccal Cell Collection
Buccal cells were collected for frataxin protein analysis as
previously described A total of three swabs were used for each
subject (alternating cheeks with each swab), which were combined
in a single microcentrifuge tube containing 500 mL of ice-cold
Extraction Buffer A (Abcam, Cambridge, MA). After the final
swab was collected, the tube was immediately placed on dry ice
and stored at 280uC until further processing. To extract protein
from the buccal cells, the microcentrifuge tubes were thawed on
Frataxin Gene Expression in Friedreich’s Ataxia
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ice, incubated on ice for 20 minutes with intermittent vortexing,
and centrifuged at 20,000 g for 10 min at 4uC. The cell
supernatant containing soluble protein was transferred to a new
tube and protein was quantified using a BCA protein assay
according to the manufacturer’s protocol (Pierce Protein Research
Products, Thermo Fisher Scientific, Rockford, IL).
Frataxin Protein Measures
Frataxin protein was measured using either a dipstick lateral
flow immunoassay (Abcam) or an ELISA (Abcam). To compare
the interchangeability of the two frataxin assay formats, we
measured frataxin protein levels in PBMC extracts from five
individuals in triplicate using both methods, and the amount of
frataxin was quantified based on a rFXN standard curve. The
levels of frataxin as determined by each method were highly
correlated (R2 = 0.845).
The lateral flow immunoassay (Abcam) was performed as
previously described [23]. Briefly, 25 mg of buccal cell protein in
25 mL of Buffer A was mixed with 25 mL blocking buffer and
added to individual wells on a 96-well plate containing a gold-
conjugated anti-frataxin monoclonal antibody (mAB) in each well.
For whole blood samples, 100 mL of blood were lysed with 300 mL
of Buffer A and 25 mL of the cleared-supernatant was added to
individual wells of the 96-well plate. For measurement of frataxin
protein in fractionated whole blood, 100 mL of each cell fraction
was combined with 300 mL of Buffer A and 25 mL of the cleared-
supernatant was added to individual wells of the 96-well plate.
Tubes were incubated on ice for 30 minutes with intermittent
vortexing and centrifuged at 20,000 g for 10 min at 4uC to
remove insoluble material. Samples were incubated for 5 minutes
at room temperature, allowing the gold-conjugated antibody to
hydrate. After samples were mixed by gentle pipetting, a dipstick
was added to each well and samples were allowed to wick up the
membrane. Dipsticks were read using a Hamamatsu immuno-
chromato reader (Mitosciences dipstick reader, MS1000) and the
amount of frataxin quantified.
Using the frataxin ELISA (Abcam), 15 mg of protein derived
from PBMCs in 200 mL of ELISA incubation solution was added
to individual wells of the microplate. For whole blood, 80 mL of
blood was lysed with 240 mL ELISA lysis buffer then the lysate was
cleared of insoluble material by centrifugation at 4uC. Patient and
carrier samples were diluted 1:2 with ELISA incubation solution,
while control samples were diluted 1:4 with ELISA incubation
solution. 200 mL of each sample was added to individual wells of
the microplate. Each sample was measured in duplicate. An rFXN
standard curve was prepared and added to the microplate
according to the manufacturer’s instructions.
Frataxin RT-qPCR
The level of frataxin mRNA was measured using a TaqManH
Probe-based (Applied Biosystems, Carlsbad, CA), one-step real-
time quantitative PCR (RT-qPCR) assay. Total RNA (50 ng) was
combined with Brilliant II 1-step qRT-PCR master mix (Agilent
Technologies, Santa Clara, CA), TaqMan Gene Expression Assay
for frataxin (Hs00175940_m1), TaqMan Gene Expression Assay
for GAPDH (Applied Biosystems), and reverse transcriptase
(Agilent Technologies) in a 25 mL reaction volume. Assays were
performed in duplicate using an Mx3005 or Mx3000 instrument
and analyzed using MxPro Software (Agilent Technologies). The
amount of frataxin mRNA in each sample was determined as the
relative quantity to the calibrator where the calibrator sample was
assigned an arbitrary quantity of 1. For baseline frataxin level
measurements, RNA from control donors was the calibrator and
for frataxin level measurements in HDACi-treated PBMCs, RNA
from a DMSO-treated sample was the calibrator. Each plate
contained a No Template Control, and a No Reverse Transcrip-
tase Control was run for each sample. The relative quantity of
frataxin mRNA was normalized to RNA input and GAPDH when
baseline levels of frataxin were measured or to cell number and
RNA input when the levels of frataxin were measured in PBMCs
following treatment with HDAC inhibitor.
Statistical Analysis
For analysis of frataxin protein and mRNA stability, frataxin
protein and/or mRNA was measured from whole blood in two
different cohorts at regular intervals over the course of four weeks
(Cohort 1; n= 31) and 15 weeks (Cohort 2; n = 10). Differences in
frataxin levels between visits were analyzed using one-way
ANOVA for repeated measures with the Greenhouse-Geiser
correction for sphericity. Last observation carried forward was
used in the event of a missed clinical visit.
A further measure of frataxin protein stability, expressed as
intra-individual variability over the duration of the study, was
determined by measuring the coefficient of variation (CV) and
comparing the value to previously reported ranges for the assay
[19]. All CV values were defined as the ratio of the standard
deviation/mean over the duration of the study.
In order to investigate the ability of frataxin level to predict
disease status and progression, multivariate linear regression
models were constructed using neurological status and measured
by FARS exam or change in FARS exam as the dependent
variables, and age, sex and frataxin level as independent variables
as described previously [22,24]. In this analysis, to capture an
accurate, potentially linear rate of progression, we excluded
patients with less than two years of FARS measurements (with
fewer than three total visits) to reduce variation in disease
progression and patients with FARS scores greater than 100 to
eliminate a possible ceiling effect.
Table 1. Summary of Clinical and Demographic Values from FRDA Patients at the Children’s Hospital of Philadelphia (Cohort 1).
GAA1 GAA2 Age Age of Onset Age of Diagnosis* Duration of Disease Frataxin, % of Control
Min 126 359 18 5 8 2 5.1
Max 901 1450 58 41 46 30 91.2
Median 549 848 29 13 17 11 38.4
Mean 534.9 863.1 31.8 15.7 18.4 11.2 38.5
Demographic information for subjects at Children’s Hospital of Philadelphia study (n = 31);
*Denotes n = 24 for those particular demographic data; Sex was evenly distributed (13 female/13 male).
doi:10.1371/journal.pone.0063958.t001
Frataxin Gene Expression in Friedreich’s Ataxia
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All data analyses were performed using Stata SE 11 software,
Microsoft Office Excel 2007, and GraphPad Prism 5.0. A p-value
of ,0.05 was considered statistically significant.
Results and Discussion
Relation of Clinical Information to Frataxin Levels
Clinical and demographic information for the FRDA patients in
Cohort 1 in this study is summarized in Table 1. Patients in
Cohort 1 (n = 31) were observed systematically over four weeks to
examine short-term reproducibility and stability of frataxin
measurements and to determine the extent to which demographic
information correlates with disease severity or frataxin protein
level. A strong inverse hyperbolic correlation (R2= 0.794,
p,0.001) between age of disease onset and GAA repeat length
on the shorter allele (GAA1) was observed, in agreement with
previous studies [19,25–27]. An inverse correlation was observed
between GAA1 repeat length and frataxin protein level measured
in whole blood from patients in Cohort 1 (R2 = 0.58, p,0.001).
Although GAA repeat length highly correlated with age of onset
and the level of frataxin protein, there was only a moderate direct
correlation (R2 = 0.38, p,0.001) between age of onset and level of
Figure 1. Frataxin protein and mRNA level is stable from day-to-day in whole blood. (A) Frataxin protein levels measured by dipstick assay
in FRDA patient subjects over the course of 4 weeks (Cohort 1; n = 31). (B) Frataxin protein levels measured by dipstick assay in whole blood collected
from 5 FRDA patients (red) and 5 related carriers (blue) weekly for 15 weeks (Cohort 2). (C) Frataxin mRNA levels measured by RT-qPCR in blood
collected in PAXgene tubes from Cohort 2. Frataxin mRNA level is expressed relative to control donor levels and is normalized to the endogenous
control gene GAPDH.
doi:10.1371/journal.pone.0063958.g001
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Figure 2. Frataxin protein and mRNA levels strongly correlated when measured in different cellular compartments (Cohort 3). (A)
Frataxin mRNA in PBMCs and whole blood (R2 = 0.84, p,0.0001). (B) Frataxin protein in PBMCs and whole blood (R2 = 0.63, p,0.0001). (C) Frataxin
mRNA and protein in whole blood (R2 = 0.55, p,0.0001). (D) Frataxin mRNA and protein in PBMCs (R2 = 0.58, p,0.0001). (E) Frataxin protein in PBMCs
and cheek swabs (R2 = 0.67, p,0.0001). (F) Frataxin protein in whole blood and cheek swabs (R2 = 0.58, p,0.0001). Frataxin mRNA level in PBMCs and
whole blood is expressed relative to control donor levels and is normalized to the endogenous control gene GAPDH.
doi:10.1371/journal.pone.0063958.g002
Frataxin Gene Expression in Friedreich’s Ataxia
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frataxin protein. The duration of disease did not correlate with
frataxin protein levels, indicating that this cohort contains patients
at various stages of disease progression.
Frataxin Protein and mRNA Expression is Stable Over
Time
Frataxin protein level measured in whole blood from patients in
Cohort 1 remained stable over the course of three clinic visits
conducted over a period of 4 weeks (Figure 1A). Based on one-way
ANOVA for repeated measures, there were no significant
differences in frataxin levels between any of the clinical visits in
Cohort 1 (p = 0.352). The intra- and inter-assay variability was
within the previously reported range for this assay [19]. These data
suggest that frataxin protein level is stable over a broad range of
disease severity and do not demonstrate appreciable day-to-day
variability.
To examine longer-term stability of frataxin protein and
mRNA, measurements were made in whole blood collected from
a second cohort (Cohort 2) on a weekly basis for 15 weeks. One-
way ANOVA for repeated measures analysis revealed no
statistically significant changes in frataxin protein (p = 0.068) or
mRNA (p= 0.148) levels over the course of the study. In cohort 2,
little variability was observed in frataxin protein level over the
period of sample collection (Figure 1B). The average CV over the
duration of the study was 15.6%, within the reported variability of
the assay. While frataxin mRNA levels in whole blood collected in
PAXgene tubes were also stable over this duration (Figure 1C), the
variability was moderately higher than that observed for frataxin
protein (15.6% CV compared to 18.0% CV for protein and
mRNA, respectively).
Figure 3. Effect of HDAC inhibitor RG2833 on frataxin level in PBMCs (Cohort 3). (A) The effect of RG2833 on frataxin mRNA level relative
to vehicle control in PBMCs following 48 hour treatment (n = 49 at 1, 2.5, 5, and 10 mM; n= 2 at 0.1 and 0.5 mM). The relative quantity of frataxin mRNA
in HDACi–treated PBMCs is normalized to cell number and RNA input. (B) The effect of RG2833 on FXN protein level relative to vehicle control in
PBMCs following 72 hour treatment (n = 27). (C) The fold-change increase in FXN mRNA in PBMC in response to HDACi does not correlate with repeat
length (GAA1, R2 = 0.015, p = 0.451). (D) The fold-change increase in FXN protein in response to HDACi does not correlate with repeat length (GAA1,
R2 = 0.006, p = 0.686).
doi:10.1371/journal.pone.0063958.g003
Frataxin Gene Expression in Friedreich’s Ataxia
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e63958
The Erythrocyte Fraction is the Major Contributor to
Whole Blood Frataxin Protein
The level of frataxin protein in whole blood represents the
weighted average of the different components of blood (PBMCs,
platelets, erythrocytes, etc.). However, due to differences in the
number of mitochondria in each cell type, the numbers of each cell
type in blood, and potentially different expression levels between
cell types, certain cells may contribute more to the overall level of
frataxin protein than others. In addition, not all cell types in blood
contain a nucleus; therefore, not all cells in a whole blood sample
can directly increase the level of frataxin in response to HDACi
therapy. This is a major consideration when using peripheral
blood to monitor biologic activity for any therapeutic aimed at
increasing frataxin.
Therefore, we sought to determine the contribution of each cell
compartment to the total level of frataxin protein in blood using
separation of cell types by differential centrifugation. The majority
of the frataxin protein in whole blood was found in the erythrocyte
fraction at 78.6 ng/mL or 85% of the whole blood frataxin signal.
Platelets and PBMCs had lower frataxin levels at 7.0 ng/mL
(8.5%) and 5.5 ng/mL (6.7%), respectively. Last, the granulocyte
fraction had the least frataxin protein at 0.3 ng/mL or 0.4%.
However, separation of blood using Ficoll is not an efficient means
of granulocyte isolation, and thus the actual contribution of
granulocytes might be underestimated.
Since the majority of frataxin measured in whole blood is found
in erythrocytes, we explored measurements of frataxin in PBMCs
and cheek swabs, as frataxin in erythrocytes is unlikely to change
rapidly with therapeutics designed to increase transcription of the
FXN gene, like HDAC inhibitors.
Baseline Frataxin Protein and mRNA are Equivalent in
Whole Blood, PBMCs, and Cheek Swabs
Inorder toassess the relevanceofmeasuring frataxin inone sample
typeoveranother,wecompared frataxinmRNAandprotein levels in
whole blood, isolated PBMCs, and cheek swabs from a panel of
FRDA patients, carriers and controls (Cohort 3). Baseline frataxin
mRNA in PBMCs highly correlated with frataxin mRNA in whole
blood (R2= 0.84, p,0.0001) (Figure 2A). Similarly, frataxin protein
inPBMCscorrelatedwith frataxinprotein inwholeblood (R2= 0.63,
p,0.0001) (Figure 2B). Additionally, frataxin mRNA and protein
correlated in whole blood (R2= 0.55, p,0.0001) (Figure 2C) and in
PBMCs (R2= 0.58,p,0.0001) (Figure2D).Frataxinprotein levels in
cheek swabs correlatedwell with levels in PBMCsamples (R2 = 0.67,
p,0.0001) (Figure 2E) and whole blood (R2= 0.58, p,0.0001)
(Figure 2F).These results indicate that the frataxinmRNAorprotein
levelsmeasured inone sample typepredict levels in adifferent sample
type. Additionally, these data support the accuracy of each
measurement method and the use of buccal cells for frataxin protein
biomarker analysis in therapeutic studies.Wewere not able to isolate
quality total RNA from buccal cells and therefore could not assess
frataxin mRNA levels in this sample type.
HDACi-Induced Changes in Frataxin mRNA and Protein
are Independent of GAA Repeat Length
HDAC inhibitors such as RG2833 increase frataxin mRNA and
protein in patient lymphocytes [13,14] and in animal models of
Friedreich’s ataxia [14–16]. We examined the variability in these
measures across the patient population in Cohort 3 in order to
better understand any potential variance seen in response to
HDACi treatment in clinical trials. PBMCs were isolated from
FRDA patient blood and cultured in the presence of 1–10 mM
RG2833 or DMSO for 48 or 72 hours for frataxin mRNA or
protein measurements, respectively. RG2833 treatment of patient
derived PBMCs resulted in a dose-dependent increase in frataxin
mRNA (n= 47; Figure 3A) expressed as an average fold change
over vehicle control. With this method of PBMC culture and
mRNA quantification, $1.3 fold change in mRNA is statistically
significant. In this series of patient samples exposed to 10 mM
RG2833, 83% (39 of 47) had increased frataxin mRNA after
HDAC inhibitor treatment. We also observed similar drug-
induced changes in frataxin protein levels in patient PBMC
samples (n = 27; Figure 3B).
While it is useful to define the biochemical limit of detecting a
response to drug treatment, it is important to use this in vitro
response to estimate a potential therapeutic response during
patient treatment. The levels of frataxin mRNA and protein
observed in lymphocytes obtained from carriers are 1.5 to 2-fold
higher than seen in patient lymphocytes (data not shown). If the
RG2833 response rate in vitro is defined as the percent of patient
PBMCs that show a 1.5 or 2-fold increase in frataxin in response
to 10 mM RG2833 then the response rates are 72% and 50% of
patients tested, respectively (Table 2). For protein, the response
rates for the same fold change cutoffs are 58% and 23% response.
In order to determine whether GAA1 repeat length could be
used to predict the change in frataxin mRNA or protein in
response to RG2833, GAA1 repeat length was plotted against
frataxin response to RG2833 treatment (Figure 3C and 3D).
There was no correlation between GAA1 repeat length and
frataxin mRNA or protein response to 10 mM (R2= 0.015 and
R2= 0.006, respectively). Similarly, baseline frataxin mRNA and
response to RG2833 did not correlate (data not shown).
Relation of Frataxin Levels to Disease Severity and
Progression
Since frataxin levels are stable over time, reproducibly
measurable in peripheral tissue, and responsive to potential
therapeutic agents such as HDACi, we investigated whether
frataxin levels would predict severity of disease as measured by
FARS scores (Table 3). To do this we examined all patients in the
Collaborative Clinical Research Network (CCRN) for FRDA
patient registry, but excluded patients with less than two years of
FARS measurements (with fewer than three total visits) to reduce
variation in disease progression and patients with FARS scores
greater than 100 to eliminate a possible ceiling effect [24]. In a
linear regression model accounting for patient age and sex,
frataxin levels in whole blood predicted baseline FARS scores
(n = 94, p,0.001, R2= 0.245). This finding was supported by the
correlation between GAA1 and baseline FARS scores (p,0.001,
R2= 0.441), which suggests patients with longer GAA repeats and
lower frataxin levels have a more severe neurological phenotype.
We then investigatedwhether frataxin levelswouldpredict the rate
of diseaseprogression, asmeasuredby rateof change inFARSscores.
Table 2. Response Rate for RG2833 in PBMC Isolated From
FRDA Patients in Cohort 3 and Treated Ex Vivo.
% Response to 10 mM RG2833
1.5-Fold Increase in
Frataxin
2.0-Fold Increase in
Frataxin
Protein 58 23
mRNA 72 50
Protein, n = 52; mRNA, n = 81.
doi:10.1371/journal.pone.0063958.t002
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In previous work FARS scores were shown to increase at an average
rate of 6.267.4 points per two-year period [22]. Age, but not GAA1
repeat length, was a significant predictor of change in FARS scores,
indicatingyoungerpatientschange faster forreasonsnotbeyondtheir
longer GAA repeat length. Here, we hypothesized that patients with
lower frataxin levels would have slower disease progression as
evidenced by a smaller change in FARS score per year.We found an
overall rate of change in FARS scores of 2.362.5 points per year in
patientswithfrataxinmeasurements (n = 94), similar tothepreviously
reported rate [22]. Age was a significant predictor of disease
progression;ofFRDApatientswithrecordedfrataxinmeasurements,
adults progressed significantly slower (1.962.0 points per year) than
children under the age of 18 (3.763.3 points per year, p = 0.003).On
their own, frataxin levels did not predict change in FARS scores
(p = 0.503); however, when using multivariate regression analysis to
assess the effect of frataxin levels on rate of FARS change controlling
for the effect of age and sex, the model was statistically significant
(p = 0.002) with age as the main predictor of progression (p,0.001)
and frataxin levels approaching significance (p = 0.096). Inclusion of
frataxin level in themodel increased theR2 value by 2.7% compared
with a model not including frataxin values.
General Discussion
In the present study we have defined the quantitative features of
frataxin gene and protein measurement in relation to potential use
as a marker of therapeutic response in FRDA. Methods to monitor
the expression of the frataxin gene will thus be important
supplements to clinical metrics, particularly in response to
potential disease-modifying therapies such as HDAC inhibition.
Previous reports have observed the inverse relationship of frataxin
protein levels in blood with the size of the GAA repeat inserted in
the frataxin gene and the age of onset of the disease [25–27]. In
addition, clinical studies have investigated the effects of recombi-
nant human erythropoietin on frataxin levels in PBMCs and
lymphocytes utilizing ELISA-based methods for frataxin quanti-
fication, demonstrating that these assays are sensitive enough to
detect changes in frataxin protein levels in response to pharma-
cological treatment; however, these studies were limited by their
small sample sizes [20,25,28–32]. To-date, the practical uses of
frataxin levels as a biomarker have not been fully characterized in
studies involving a larger number of patient samples. This report
documents for the first time the effects of an experimental
therapeutic agent designed to change frataxin expression, HDAC
inhibitor RG2833, on frataxin protein levels as measured by a
lateral flow immunoassay.
For frataxin levels to be used as meaningful biomarkers in
FRDA several features of the biochemical measure must be
considered. The first critical aspect to using frataxin level to assess
biological outcome of treatment with RG2833 or other disease
modifying therapy is demonstrating the day-to-day stability of
frataxin in the cells sampled in a clinical trial. Since a two-fold
increase in frataxin is thought to be clinically relevant, it is
important that the daily biological fluctuation of frataxin is low.
Our data show that frataxin measurements as performed here
meet this criterion.
A third requirement for use of frataxin as a biomarker in FRDA
is that it must be responsive in a measurable way to interventions
in a large proportion of subjects. Prior studies in animal models
and PBMCs from patients had shown the ability to increase
frataxin expression [14,15], but here we show the first evaluation
of drug response across a population of patient samples. We found
that patients respond to HDACi, with 50% increasing frataxin
mRNA 2-fold and 72% increasing frataxin mRNA 1.5-fold.
Somewhat surprisingly, there was no correlation between GAA1
repeat length and frataxin fold-change in response to HDACi
(Fig. 3C and 3D). These results suggest that GAA1 repeat length
cannot be used to predict the degree of change in frataxin
expression, and that the strength of pharmacological response is
independent of disease severity. Finally for frataxin measurement
to be a useful biomarker, it must predict disease severity and if
possible change in disease severity. Here the data show that
frataxin is a marker of disease severity in a cross sectional manner,
and marginally predictive of ongoing change in neurological
severity, though this analysis is made difficult by the interrelation
between many variables (age, GAA repeat, length, age of onset,
frataxin level) in a small sample size.
In summary, biochemical methods to quantify frataxin mRNA
and protein levels have been developed and characterized across a
population of FRDA patients. These observations suggest that
frataxin levels can be used as a sensitive measure of treatment-
induced expression changes. A preliminary evaluation of the ex vivo
frataxin expression response rate across a population of FRDA
patients suggest that $50% may respond to HDACi treatment
with a measurable increase in frataxin. Additional characterization
to correlate frataxin measures and clinical outcome will help define
the relative significance of this biomarker in predicting clinical
benefit from experimental drug treatments.
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Table 3. Summary of Clinical Information and FRDA Disease Parameters by Frataxin Quartile.
Summary of Medians by Frataxin Quartile
Quartile N
Frataxin, % of Average
Control GAA1 Age of Onset Age at Assessment Baseline FARS FARS, Change/Year (IQR)
Q1 23 11.2 857 7 20 64 2.9 (1.2–4.0)
Q2 24 22.0 600 11 19 59.5 2.1 (0.9–3.2)
Q3 24 31.0 480 16 27 50.2 2.0 (1.2–3.7)
Q4 23 48.7 325 19 49 48 1.6 (1.0–3.0)
Data collected from the CCRN for FRDA patient registry.
doi:10.1371/journal.pone.0063958.t003
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